Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05775601 · ClinicalTrials.gov registry record · Early Phase 1
18F-LY3950321-01 Biodistribution and Safety Study
A Early Phase 1 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT05775601 is a Early Phase 1 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT05775601, a Early Phase 1 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer targeting granzyme B. The overall goal of this protocol is to evaluate the safety, tolerability, and radiation dosimetry of 18F-LY3950321.
Interventions
- PROCEDURE PET Scan
- DRUG 18F-LY3950321
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2023-04-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05775601
The ClinicalTrials.gov registry entry for NCT05775601 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET Scan is the first listed.
NCT05775601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05775601 about?
NCT05775601 is a clinical study titled "18F-LY3950321-01 Biodistribution and Safety Study". 18F-LY3950321 (also known as 18F-MNI-1256) is a radiolabeled positron emission tomography (PET) tracer targeting granzyme B. The overall goal of this protocol is to evaluate the safety, tolerability, and radiation dosimetry of 18F-LY3950321.
What is the current status of trial NCT05775601?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2023-02-28. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT05775601?
The interventions under investigation include: PET Scan (PROCEDURE), 18F-LY3950321 (DRUG).
Who is sponsoring clinical trial NCT05775601?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.